Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Panbela Therapeutics, Inc. (PBLA)
USD0.01
+0.00 (+0.00%)
US OTC Healthcare Biotechnology
Address
712 Vista Boulevard 55387
Waconia, MN, US
Waconia, MN, US
CEO
Jennifer K. Simpson
Website
panbela.com
IPO
2017-01-03
CIK 1029125 ISIN US69833W4042
Description
Panbela Therapeutics, Inc. is a biopharmaceutical enterprise currently in clinical development, along with its subsidiaries, dedicated to advancing innovative therapies for cancer patients. The company's therapeutic endeavors primarily target pancreatic disorders, including pancreatitis, pancreatic cancer, and neoadjuvant pancreatic cancer. Beyond pancreatic diseases, they are also exploring treatments for colorectal cancer, ovarian cancer, and various other oncology indications. Their flagship experimental drug, SBP-101, is currently undergoing Phase Ia/Ib clinical trials, specifically intended for individuals diagnosed with metastatic pancreatic ductal adenocarcinoma. Established in 2011, the company, headquartered in Waconia, Minnesota, rebranded from its prior name, Sun BioPharma, Inc., to Panbela Therapeutics, Inc. in December 2020.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.01
+0.00 (+0.00%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
1.2K
Beta
1.88
Float Shares
4.85M
Free Float %
100.0%
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (3 ratings, all time)
Buy
Price Targets & DCF
Current price
0.01
Ratings Trend (MoM)
100% Bullish
| Rating | 2024-12 | Change |
|---|---|---|
| Strong Buy | 1 | 0 |
| Buy | 0 | -1 |
| Hold | 0 | -1 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-60.79
Distress
Piotroski F-Score
4 / 9
Average
MOAT Score
2 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%-470.4% Q3'24: +97.2% (vs Q3'23)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%— Q3'24: +225.9% (vs Q3'23)
-
Share dilution Biotechnology: -3.4%+364,521.7% Q3'24: +3,231.4% (vs Q3'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.10× Q3'24: -0.24× (vs Q3'23)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
—
|
—
est.
|
—
est.
|
8.40M
8.40M – 8.40M
|
34.90M
34.90M – 34.90M
+315.5% YoY
|
83.80M
83.80M – 83.80M
+140.1% YoY
|
| EBITDA |
-51.29M
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| EBIT |
-25.77M
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| Net Income |
-25.26M
est: -56.44M (+55.2%)
|
-21.13M
est.
|
-13.88M
est.
|
-10.72M
-10.72M – -10.72M
+22.7% YoY
|
-4.85M
-4.85M – -4.85M
+54.8% YoY
|
31.3K
31.3K – 31.3K
+100.6% YoY
|
| SGA |
5.03M
|
—
est.
|
—
est.
|
—
— – —
|
—
— – —
|
—
— – —
|
| EPS |
-232,429.55
est: -18.06 (-1,287,084.9%)
|
-6.76
est.
|
-4.44
est.
|
-3.43
-3.43 – -3.43
+22.7% YoY
|
-1.55
-1.55 – -1.55
+54.8% YoY
|
0.01
0.01 – 0.01
+100.6% YoY
|
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-3.75M
OE per share TTM
-593.93
Owner's Yield
-386,198.85%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
1.0%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
15
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Douglas M. Polinsky | 2.71M | 8.60% | 2.71M | — | 2.71M | — | IN | USA | 2015-09-14 | ↗ |
| 2 | Clifford F. McCurdy III | 2.66M | 8.70% | 2.66M | — | 2.66M | — | IN | USA | 2015-09-14 | ↗ |
| 3 | Nant Capital, LLC | 2.43M | 33.33% | — | 2.43M | — | — | OO | — | 2024-10-29 | ↗ |
| 4 | Patrick Soon-Shiong | 2.43M | 33.33% | — | 2.43M | — | — | IN | — | 2024-10-29 | ↗ |
| 5 | Christopher R. Johnson | 2.18M | 7.10% | 2.18M | — | 2.18M | — | IN | USA | 2015-09-14 | ↗ |
| 6 | Ryan R. Gilbertson 2012 Irrevocable Family Trust | 1.67M | 5.40% | 1.67M | — | 1.67M | — | OO | Minnesota | 2015-09-14 | ↗ |
| 7 | Michael T. Cullen | 873.3K | 6.30% | 873.3K | — | 873.3K | — | IN | citizenship or place of organization | 2022-02-14 | ↗ |
| 8 | Jeff Easton | 590.0K | 9.90% | 590.0K | — | 590.0K | — | IN | United States | 2023-01-30 | ↗ |
| 9 | Lind Global Fund II LP | 590.0K | 9.90% | 590.0K | — | 590.0K | — | PN | Delaware | 2023-01-30 | ↗ |
| 10 | Lind Global Partners II LLC | 590.0K | 9.90% | 590.0K | — | 590.0K | — | OO | Delaware | 2023-01-30 | ↗ |
| 11 | Armistice Capital Master Fund Ltd. | 497.0K | 4.99% | — | 497.0K | — | 497.0K | CO | Delaware | 2020-09-08 | ↗ |
| 12 | Armistice Capital, LLC | 497.0K | 4.99% | — | 497.0K | — | 497.0K | IA, OO | Delaware | 2020-09-08 | ↗ |
| 13 | Steven Boyd | 497.0K | 4.99% | — | 497.0K | — | 497.0K | HC, IN | Delaware | 2020-09-08 | ↗ |
| 14 | D. Robert Schemel | 450.6K | 4.60% | 157.0K | 293.7K | 157.0K | 293.7K | IN | citizenship or place of organization | 2021-02-16 | ↗ |
| 15 | Paul M. Herron | 236.1K | 4.60% | 199.5K | 36.6K | 199.5K | 36.6K | IN | USA | 2019-02-14 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
2
Sells
0
Shares acquired
98.3K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+98,280
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-11-15 | Nant Capital, LLC | 10% Owner | P-Purchase | A | 8% Senior Convertible Note due 2025 | 0 | 0.37 | — | 0 | D | ↗ |
| 2024-10-22 | Nant Capital, LLC | 10% Owner | — | — | 8% Senior Convertible Tranche A Note due 2025 | 7,702,702 | 0.37 | 2.85M | 0 | D | ↗ |
| 2024-10-01 | Simpson Jennifer K. | Director / Officer | A-Award | A | Stock Option (right to buy) | 72,800 | 0.39 | 28.3K | 72,800 | D | ↗ |
| 2024-10-01 | Horvath Susan | Officer | A-Award | A | Stock Option (right to buy) | 25,480 | 0.39 | 9.9K | 25,480 | D | ↗ |
| 2023-11-08 | GOLDMAN SACHS GROUP INC | 10% Owner | S-Sale | D | Common Stock | 72,874 | 0.71 | 51.7K | 397,954 | — | ↗ |
| 2023-11-07 | GOLDMAN SACHS GROUP INC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 360,464 | — | ↗ |
| 2023-09-12 | Jacob Jeffrey E. | Director | G-Gift | D | Common Stock | 275 | 0.00 | — | 0 | — | ↗ |
| 2023-03-27 | Simpson Jennifer K. | Director / Officer | A-Award | A | Stock Option (right to buy) | 99,383 | 0.50 | 49.7K | 99,383 | — | ↗ |
| 2023-03-27 | Schemel Donald Robert | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,333 | 0.50 | 4.2K | 8,333 | — | ↗ |
| 2023-03-27 | MATHIESEN JEFFREY S | Director | A-Award | A | Stock Option (right to buy) | 8,333 | 0.50 | 4.2K | 8,333 | — | ↗ |
| 2023-03-27 | Jacob Jeffrey E. | Director | A-Award | A | Stock Option (right to buy) | 8,333 | 0.50 | 4.2K | 8,333 | — | ↗ |
| 2023-03-27 | Horvath Susan | Officer | A-Award | A | Stock Option (right to buy) | 34,369 | 0.50 | 17.2K | 34,369 | — | ↗ |
| 2023-03-27 | Fratamico Arthur | Director | A-Award | A | Stock Option (right to buy) | 8,333 | 0.50 | 4.2K | 8,333 | — | ↗ |
| 2023-03-27 | Donovan Daniel | Director | A-Award | A | Stock Option (right to buy) | 8,333 | 0.50 | 4.2K | 8,333 | — | ↗ |
| 2023-03-27 | Cullen Michael T. | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 8,333 | 0.50 | 4.2K | 8,333 | — | ↗ |
| 2023-01-30 | Simpson Jennifer K. | Director / Officer | P-Purchase | A | Warrants (right to buy) | 8,888 | 2.75 | 24.4K | 8,888 | — | ↗ |
| 2023-01-30 | Horvath Susan | Officer | P-Purchase | A | Common Stock | 4,444 | 2.25 | 10.0K | 17,880 | — | ↗ |
| 2022-10-04 | Schemel Donald Robert | Director | P-Purchase | A | Common Stock | 200,000 | 0.00 | — | 482,654 | — | ↗ |
| 2022-10-04 | Jacob Jeffrey E. | Director | P-Purchase | A | Warrants (right to buy) | 49,500 | 0.00 | — | 49,500 | — | ↗ |
| 2022-10-04 | Cullen Michael T. | Director | P-Purchase | A | Common Stock | 165,000 | 0.00 | — | 369,576 | — | ↗ |
| 2022-06-15 | Jacob Jeffrey E. | Director | — | D | Stock Option (right to buy) | 177,715 | 0.22 | 39.1K | 0 | — | ↗ |
| 2022-06-15 | Donovan Daniel | Director | — | I | Common Stock | 0 | 0.00 | — | 75,528 | — | ↗ |
| 2021-09-13 | Simpson Jennifer K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 19,125 | 2.26 | 43.2K | 19,125 | — | ↗ |
| 2021-09-13 | Horvath Susan | Officer | A-Award | A | Employee Stock Option (right to buy) | 12,135 | 2.26 | 27.4K | 12,135 | — | ↗ |
| 2021-05-25 | Schemel Donald Robert | Director / 10% Owner | A-Award | A | Common Stock | 4,316 | 0.00 | — | 96,619 | — | ↗ |
| 2021-05-25 | Schaffer Paul W. | Director | A-Award | A | Stock Option (right to buy) | 12,368 | 4.17 | 51.6K | 12,368 | — | ↗ |
| 2021-05-25 | MATHIESEN JEFFREY S | Director | A-Award | A | Stock Option (right to buy) | 12,368 | 4.17 | 51.6K | 12,368 | — | ↗ |
| 2021-05-25 | Fratamico Arthur | Director | A-Award | A | Common Stock | 4,316 | 0.00 | — | 9,615 | — | ↗ |
| 2021-05-25 | Cullen Michael T. | Director / 10% Owner | A-Award | A | Common Stock | 4,316 | 0.00 | — | 216,811 | — | ↗ |
| 2021-04-29 | Gagnon Suzanne | Director | G-Gift | D | Common Stock | 1,000 | 0.00 | — | 0 | — | ↗ |
| 2021-03-30 | Simpson Jennifer K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 170,000 | 4.09 | 695.3K | 170,000 | — | ↗ |
| 2021-03-30 | Horvath Susan | Officer | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 4.09 | 163.6K | 40,000 | — | ↗ |
| 2021-03-30 | Gagnon Suzanne | Director | A-Award | A | Employee Stock Option (right to buy) | 35,000 | 4.09 | 143.2K | 35,000 | — | ↗ |
| 2021-03-30 | Cullen Michael T. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 55,000 | 4.09 | 225.0K | 55,000 | — | ↗ |
| 2021-01-06 | Gagnon Suzanne | Director | G-Gift | D | Common Stock | 7,142 | 0.00 | — | 1,000 | — | ↗ |
| 2020-12-01 | Schemel Donald Robert | Director / 10% Owner | A-Award | A | Common Stock | 2,875 | 0.00 | — | 92,303 | — | ↗ |
| 2020-12-01 | Schaffer Paul W. | Director | A-Award | A | Common Stock | 2,875 | 0.00 | — | 162,295 | — | ↗ |
| 2020-12-01 | MATHIESEN JEFFREY S | Director | A-Award | A | Common Stock | 2,875 | 0.00 | — | 5,875 | — | ↗ |
| 2020-12-01 | Fratamico Arthur | Director | A-Award | A | Common Stock | 2,875 | 0.00 | — | 5,299 | — | ↗ |
| 2020-09-10 | Simpson Jennifer K. | Director / Officer | P-Purchase | A | Common Stock | 1,000 | 2.74 | 2.7K | 3,424 | — | ↗ |
| 2020-09-08 | Schaffer Paul W. | Director | P-Purchase | A | Common Stock | 225 | 2.55 | 573.75 | 159,420 | — | ↗ |
| 2020-09-04 | Schaffer Paul W. | Director | P-Purchase | A | Common Stock | 24,775 | 2.51 | 62.2K | 159,195 | — | ↗ |
| 2020-09-01 | Simpson Jennifer K. | Director / Officer | P-Purchase | A | Warrant (right to buy) | 2,424 | 4.54 | 11.0K | 2,424 | — | ↗ |
| 2020-09-01 | Horvath Susan | Officer | P-Purchase | A | Warrant (right to buy) | 2,424 | 4.54 | 11.0K | 2,424 | — | ↗ |
| 2020-09-01 | Fratamico Arthur | Director | P-Purchase | A | Common Stock | 2,424 | 4.13 | 10.0K | 2,424 | — | ↗ |
| 2020-09-01 | Cullen Michael T. | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 4.13 | 41.3K | 207,995 | — | ↗ |
| 2020-07-15 | Simpson Jennifer K. | Director / Officer | A-Award | A | Employee Stock Option (right to buy) | 212,048 | 9.99 | 2.12M | 212,048 | — | ↗ |
| 2020-06-24 | Schemel Donald Robert | Director / 10% Owner | A-Award | A | Stock Option (right to buy) | 13,700 | 4.98 | 68.2K | 13,700 | — | ↗ |
| 2020-06-24 | Schaffer Paul W. | Director | A-Award | A | Stock Option (right to buy) | 13,700 | 4.98 | 68.2K | 13,700 | — | ↗ |
| 2020-06-24 | MATHIESEN JEFFREY S | Director | A-Award | A | Stock Option (right to buy) | 13,700 | 4.98 | 68.2K | 13,700 | — | ↗ |
| 2020-06-24 | Horvath Susan | Officer | A-Award | A | Employee Stock Option (right to buy) | 32,000 | 4.98 | 159.4K | 32,000 | — | ↗ |
| 2020-06-24 | Gagnon Suzanne | Director | A-Award | A | Employee Stock Option (right to buy) | 40,000 | 4.98 | 199.2K | 40,000 | — | ↗ |
| 2020-06-24 | Fratamico Arthur | Director | A-Award | A | Stock Option (right to buy) | 12,000 | 4.98 | 59.8K | 12,000 | — | ↗ |
| 2020-06-24 | Cullen Michael T. | Director / Officer / 10% Owner | A-Award | A | Employee Stock Option (right to buy) | 50,000 | 4.98 | 249.0K | 50,000 | — | ↗ |
| 2020-06-05 | Schaffer Paul W. | Director | P-Purchase | A | Common Stock | 10,000 | 4.00 | 40.0K | 134,420 | — | ↗ |
| 2020-06-05 | Horvath Susan | Officer | P-Purchase | A | Warrant (right to buy) | 2,500 | 6.00 | 15.0K | 2,500 | — | ↗ |
| 2020-05-22 | Cullen Michael T. | Director / Officer / 10% Owner | P-Purchase | A | Common Stock | 10,000 | 4.00 | 40.0K | 204,576 | — | ↗ |
| 2019-12-16 | Fratamico Arthur | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2018-04-17 | Horvath Susan | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-12-31 | Cullen Michael T. | Director | — | D | Common Stock | 0 | 0.00 | — | 1,620,000 | — | ↗ |
| 2016-03-03 | Gill Dalvir S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-10-01 | Kellen Scott | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-24 | PAULSON J ROBERT JR | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-24 | MATHIESEN JEFFREY S | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-04 | Ryweck Daniel E. | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-09-04 | KAYSEN DAVID B | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
Executive team
Top executives
Shares Outstanding
4.85M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2022 | Jennifer K. Simpson President and Chief Executive Officer | 506.0K | — | — | — | 188.3K | — | 694.3K | 0.00% | ↗ |
| 2 | 2022 | Susan Horvath Chief Financial Officer and Vice President of Finance | 320.0K | — | — | — | 103.5K | — | 423.5K | 0.00% | ↗ |
| 3 | 2021 | Jennifer K. Simpson President and Chief Executive Officer (c) | 476.6K | — | — | 537.7K | 182.4K | — | 1.20M | 44.93% | ↗ |
| 4 | 2021 | Jennifer K. Simpson President and Chief Executive Officer | 476.6K | — | — | 537.7K | 182.4K | — | 1.20M | 44.93% | ↗ |
| 5 | 2021 | Susan Horvath Chief Financial Officer and Vice President of Finance | 302.2K | — | — | 155.3K | 99.6K | — | 557.1K | 27.87% | ↗ |
| 6 | 2021 | Susan Horvath Chief Financial Officer and Vice President of Finance | 302.2K | — | — | 155.3K | 99.6K | — | 557.1K | 27.87% | ↗ |
| 7 | 2021 | Michael T. Cullen Former Executive Chairman (d) | 337.1K | — | 18.0K | 200.2K | — | — | 555.3K | 39.29% | ↗ |
| 8 | 2020 | Jennifer K. Simpson President and Chief Executive Officer (c) | 145.6K | — | — | 1.53M | 78.8K | — | 1.75M | 87.21% | ↗ |
| 9 | 2020 | Michael T. Cullen Former Executive Chairman (d) | 316.0K | — | — | 179.9K | 141.8K | — | 637.7K | 28.21% | ↗ |
| 10 | 2020 | Michael T. Cullen Executive Chairman (c) | 316.0K | — | — | 153.4K | 141.8K | — | 611.2K | 25.10% | ↗ |
| 11 | 2020 | Susan Horvath Chief Financial Officer and Vice President of Finance | 226.0K | — | — | 98.2K | 90.0K | — | 414.2K | 23.70% | ↗ |
| 12 | 2020 | Susan Horvath Chief Financial Officer and Vice President of Finance | 226.0K | — | — | 98.2K | 90.0K | — | 414.2K | 23.70% | ↗ |
| 13 | 2019 | Michael T. Cullen Executive Chairman , President and Chief Executive Officer ( b ) | 282.4K | — | — | 377.5K | — | — | 659.8K | 57.21% | ↗ |
| 14 | 2019 | Michael T. Cullen Executive Chairman (c) | 282.4K | — | — | 377.5K | — | — | 659.8K | 57.21% | ↗ |
| 15 | 2019 | Susan Horvath Chief Financial Officer and Vice President of Finance | 220.3K | — | — | 181.1K | — | — | 401.4K | 45.12% | ↗ |
| 16 | 2019 | Susan Horvath Chief Financial Officer and Vice President of Finance ( c ) | 220.3K | — | — | 181.1K | — | — | 401.4K | 45.12% | ↗ |
| 17 | 2018 | Michael T. Cullen Executive Chairman , President and Chief Executive Officer (b) | 221.2K | — | — | — | — | — | 712.7K | 0.00% | ↗ |
| 18 | 2018 | Michael T. Cullen Executive Chairman , President and Chief Executive Officer ( b ) | 221.2K | — | — | 491.5K | — | — | 712.7K | 68.96% | ↗ |
| 19 | 2018 | David B. Kaysen Former President and Chief Executive Officer (d) | 236.3K | — | — | — | — | — | 482.0K | 0.00% | ↗ |
| 20 | 2018 | Susan Horvath Chief Financial Officer and Vice President of Finance ( c ) | 150.0K | — | — | 147.6K | — | — | 297.6K | 49.59% | ↗ |
| 21 | 2018 | Susan Horvath Chief Financial Officer and Vice President of Finance ( c ) | 150.0K | — | — | — | — | — | 297.6K | 0.00% | ↗ |
| 22 | 2018 | Scott Kellen Former Chief Financial Officer and Vice President of Finance (e) | 25.0K | — | — | — | — | — | 147.9K | 0.00% | ↗ |
| 23 | 2017 | David B. Kaysen Former President and Chief Executive Officer (d) | 302.5K | — | — | — | — | — | 302.5K | 0.00% | ↗ |
| 24 | 2017 | Michael T. Cullen Executive Chairman , President and Chief Executive Officer (b) | 208.0K | — | — | — | — | — | 208.0K | 0.00% | ↗ |
| 25 | 2017 | Scott Kellen Former Chief Financial Officer and Vice President of Finance (e) | 173.3K | — | — | — | — | — | 173.3K | 0.00% | ↗ |
| 26 | 2017 | Scott Kellen Chief Financial Officer and Vice President of Finance | 173.3K | — | — | — | — | — | 173.3K | 0.00% | ↗ |
| 27 | 2016 | David B. Kaysen President and Chief Executive Officer | 248.9K | — | — | 1.02M | — | — | 1.27M | 80.34% | ↗ |
| 28 | 2016 | Scott Kellen Chief Financial Officer and Vice President of Finance | 209.0K | — | — | 435.7K | — | — | 644.8K | 67.58% | ↗ |
| 29 | 2016 | Michael T. Cullen Executive Chairman | 199.4K | — | — | 145.2K | — | — | 344.6K | 42.15% | ↗ |
| 30 | 2015 | Michael T. Cullen Executive Chairman and | 90.0K | — | — | 140.0K | — | — | 230.0K | 60.87% | ↗ |
| 31 | 2015 | Michael T. Cullen Executive Chairman | 90.0K | — | — | 140.0K | — | — | 230.0K | 60.87% | ↗ |
| 32 | 2015 | Clifford F. McCurdy, III Former Chairman and | 46.7K | — | — | 140.0K | — | — | 187.0K | 74.87% | ↗ |
| 33 | 2015 | David B. Kaysen President and Chief Executive Officer | 78.0K | — | — | — | — | — | 78.0K | 0.00% | ↗ |
| 34 | 2015 | David B. Kaysen President and Chief Executive Officer | 78.0K | — | — | — | — | — | 78.0K | 0.00% | ↗ |
| 35 | 2015 | Scott Kellen Chief Financial Officer and Vice President of Finance | 50.0K | — | — | — | — | — | 50.0K | 0.00% | ↗ |
| 36 | 2015 | Scott Kellen Chief Financial Officer and Vice President of Finance | 50.0K | — | — | — | — | — | 50.0K | 0.00% | ↗ |
| 37 | 2014 | Clifford F. McCurdy, III Former Chairman and | 105.0K | — | — | — | — | — | 105.0K | 0.00% | ↗ |
| 38 | 2014 | Michael T. Cullen Executive Chairman and | 70.0K | — | — | — | — | — | 70.0K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
No proxy statements available for this company yet.
Recent SEC filings
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Jennifer K. Simpson | Chief Executive Officer, President & Director | 527.0K | — |
| Susan Horvath | Vice President of Finance, Chief Financial Officer, Secretary & Treasurer | 452.4K | female |
| Tammy Groene | Vice President of Operations | — | female |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for PBLA
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
